First-In-Human Study of 211At-CD45 Radioimmunotherapy With Nonmyeloablative Conditioning Hematopoietic Cell Transplantation for Adults With Hematologic Malignancies.
Oct 2026· Journal of Clinical Oncology· pp.
JCO2600877
· 0 citations· 41 references
Medicine
TL;DR
211At-CD45 RIT can be incorporated into nonmyeloablative conditioning, with liver toxicity defining activity limits, and evidence of antitumor efficacy supports phase II evaluation.
Abstract
Purpose
Relapse is the dominant cause of failure after allogeneic hematopoietic cell transplantation (HCT) for aggressive hematologic malignancies. CD45-directed radioimmunotherapy (RIT) has been investigated to intensify conditioning and augment antitumor efficacy. After gaining clinical experience with β-emitting radionuclides, attention is now shifting toward α-emitters, such as astatine-211 (211At), for their more potent and precise radiation delivery with minimized toxicity to surrounding tissues.
PATIENTS AND
Methods
To our knowledge, in this first-in-human, two-stage dose-finding study, we administered a single infusion of 211At-labeled anti-CD45 monoclonal antibody before nonmyeloablative conditioning with fludarabine/2-3 Gy total body irradiation and allografting from HLA-matched or single-allele-mismatched donors in 45 adults (38-74 years of age) at a high relapse risk from myeloid malignancies or acute leukemia.
Results
Seventeen patients were treated in stage I with 85-591 μCi/kg of 211At. The patient receiving 591 μCi/kg developed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS), thereby establishing 500 μCi/kg as the protocol-defined maximum tolerated dose and prompting initiation of stage II at that dose in 28 patients. Infusion reactions were mild. 211At-CD45 RIT did not delay hematopoietic recovery, impair donor chimerism, or increase graft-versus-host disease (GVHD) rates. In stage II, six patients (all receiving sirolimus as part of GVHD prophylaxis for unrelated donor HCT) experienced VOD/SOS. Among the 13 patients with circulating blasts at baseline, blasts cleared in 12 before initiation of fludarabine/total body irradiation, demonstrating immediate cytotoxic activity. Estimated 1-year relapse-free and overall survival were 42% (95% CI, 28%-56%) and 49% (34%-62%), respectively.
Conclusion
211At-CD45 RIT can be incorporated into nonmyeloablative conditioning, with liver toxicity defining activity limits. Evidence of antitumor efficacy supports phase II evaluation.
Improved survival in multiple myeloma (MM) patients after high-dose chemotherapy, autologous hematopoietic cell transplantation (auto-HCT), and novel agents has led to an increasing incidence of therapy-related hematological malignancies (t-HM), although optimal management remains unclear, particularly the role of allo...
M. Maulhardt, A. Angleitner, J. Büntzel et al.· Frontiers in Oncology· 0 citations
BACKGROUND
Allogeneic hematopoietic cell transplantation (HCT) remains a potentially curative therapy for a broad range of hematologic malignancies. Early attempts to reduce graftversus-host disease (GVHD), particularly through in vitro T-cell depletion, underscored the central role of donor immune cells in disease con...
L. Honorato, M. Savioli, A. Ribeiro et al.· Transplantation and Cellular...· 0 citations
BACKGROUND
Rabbit antithymocyte globulin (rATG) plays a critical role in preventing graft-versus-host disease (GVHD) after haploidentical hematopoietic stem cell transplantation (haplo-HSCT). However, conventional weight-based dosing results in substantial interpatient variability in active rATG exposure, potentially a...
Rui Gao, Chen-Rong Huang, Xiao-Xue Liu et al.· Transplantation and Cellular...· 0 citations
Analysis of the short- and long-term outcomes in relation to HDCT regimens revealed the best rates achieved by the LEAM program, however, the multivariate regression analysis excluded the value of HDCT regimens for OS in r/r cHL.
G. Petrova, И. С. Монин, N. Zolotaikina et al.· Clinical oncohematology· 0 citations
Relapsed B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic hematopoietic stem-cell transplantation (allo-HSCT), particularly with extramedullary disease (EMD), has a dismal prognosis. The efficacy and durability of allogeneic chimeric antigen receptor T cell (allo-CAR-T) therapy in this setting remain...
Rui Liu, Jian Zhang, Ying Li et al.· Cancer Immunology and Immuno...· 0 citations
PreDLI is a safe and effective intervention in pediatric transplantation, particularly as repeated, escalating doses, while acknowledging that standardization remains challenging and outcome depends on center experience and indication.
Carmen Junk, S. Michaelis, M. Döring et al.· Pediatric Blood & Cancer· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.